A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Trial Profile

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-052
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 21 Jul 2017 According to a Merck AG media release, based on the data from KEYNOTE-045 and KEYNOTE-052 trials, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Updated results (Data cut off Dec 19, 2016) of efficacy and safety, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top